HRH2, histamine receptor H2, 3274

N. diseases: 44; N. variants: 1
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis 		0.010 Biomarker disease BEFREE The association of SNPs in HRH2 with incident HF was characterized using Cox proportional hazards regression among participants in the Multi-Ethnic Study of Atherosclerosis. 29191567 2018
CUI: C0007193
Disease: Cardiomyopathy, Dilated
Cardiomyopathy, Dilated 		0.010 AlteredExpression group BEFREE Differences in myocardial HRH2 transcript abundance were seen in participants with dilated cardiomyopathy who responded to β blockade. 29191567 2018
CUI: C0018801
Disease: Heart failure
Heart failure 		0.010 Biomarker disease BEFREE The association of SNPs in HRH2 with incident HF was characterized using Cox proportional hazards regression among participants in the Multi-Ethnic Study of Atherosclerosis. 29191567 2018
CUI: C0027498
Disease: Nausea and vomiting
Nausea and vomiting 		0.010 Biomarker phenotype BEFREE Strong recommendations for element use were given for preoperative (antenatal education and counselling, use of antacids and histamine, H2 receptor antagonists, 2-hour fasting and small meal within 6 hours surgery, antimicrobial prophylaxis and skin preparation/chlorhexidine-alcohol), intraoperative (regional anesthesia, prevention of maternal hypothermia [forced warm air, warmed intravenous fluids, room temperature]), perioperative (fluid management for euvolemia and neonatal immediate care needs that include delayed cord clamping), and postoperative (fluid management to prevent nausea and vomiting, antiemetic use, analgesia with nonsteroidal antiinflammatory drugs/paracetamol, regular diet within 2 hours, tight capillary glucose control, pneumatic compression stocking for venous thromboembolism prophylaxis, immediate removal of urinary catheter). 30240657 2018
CUI: C1335302
Disease: Pancreatic Ductal Adenocarcinoma
Pancreatic Ductal Adenocarcinoma 		0.010 Biomarker disease BEFREE Drug-drug interactions of metformin with proton pump inhibitors and histamine H2-receptor antagonists may be of clinical relevance and pertinent to future research of metformin in pancreatic ductal adenocarcinoma. 30159732 2018
CUI: C3266262
Disease: Multiple Chronic Conditions
Multiple Chronic Conditions 		0.010 Biomarker disease BEFREE The association of SNPs in HRH2 with incident HF was characterized using Cox proportional hazards regression among participants in the Multi-Ethnic Study of Atherosclerosis. 29191567 2018
CUI: C0017150
Disease: Gastrinoma
Gastrinoma 		0.010 Biomarker disease BEFREE Treatment of gastrinoma include both proton pump inhibitors (PPIs) and histamine H2 - receptor antagonists. 28507564 2017
CUI: C0017178
Disease: Gastrointestinal Diseases
Gastrointestinal Diseases 		0.010 Biomarker group BEFREE Lafutidine, a histamine H2 receptor antagonist with mucosal protective properties via sensory afferent neurons, is used for the treatment of upper gastrointestinal diseases. 28456772 2017
CUI: C0521585
Disease: Gastrointestinal mucositis
Gastrointestinal mucositis 		0.010 Biomarker disease BEFREE Lafutidine, a histamine H2 receptor antagonist with mucosal protective properties, attenuates 5-fluorouracil-induced intestinal mucositis in mice through activation of extrinsic primary afferent neurons. 28456772 2017
CUI: C0948089
Disease: Acute Coronary Syndrome
Acute Coronary Syndrome 		0.010 GeneticVariation disease BEFREE We included patients over age 64 admitted to a tertiary care hospital between 2009-2010 with heart failure, pneumonia, or acute coronary syndrome who were taking a medication in any of six commonly-interchanged classes on admission: proton pump inhibitors (PPIs), histamine H2-receptor antagonists (H2 blockers), hydroxymethylglutaryl CoA reductase inhibitors (statins), angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and inhaled corticosteroids (ICS). 29049325 2017
CUI: C0004364
Disease: Autoimmune Diseases
Autoimmune Diseases 		0.010 Biomarker group BEFREE We generated transgenic mice expressing H2R specifically in T cells on the H2RKO background, and, using wild-type B6 and H2RKO mice as controls, induced EAE either in the presence or absence of the ancillary adjuvant pertussis toxin (PTX), which models the effects of infectious inflammatory stimuli on autoimmune disease. 24371118 2014
CUI: C0014070
Disease: Encephalomyelitis
Encephalomyelitis 		0.010 Biomarker disease BEFREE We generated transgenic mice expressing H2R specifically in T cells on the H2RKO background, and, using wild-type B6 and H2RKO mice as controls, induced EAE either in the presence or absence of the ancillary adjuvant pertussis toxin (PTX), which models the effects of infectious inflammatory stimuli on autoimmune disease. 24371118 2014
CUI: C2921627
Disease: Clinically isolated syndrome
Clinically isolated syndrome 		0.010 Biomarker disease BEFREE In this study we analyzed the gene expression of histamine receptor 1 (HRH1), HRH2 and HRH4 in peripheral blood mononuclear cells derived from patients with clinically isolated syndrome (CIS), relapsing-remitting (RR) MS, secondary-progressive (SP) MS, primary-progressive (PP) MS, and healthy controls (HC). 25293806 2014
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach 		0.010 GeneticVariation disease BEFREE Association between common genetic variant of HRH2 and gastric cancer risk. 22615049 2012
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma 		0.010 GeneticVariation disease BEFREE Association between common genetic variant of HRH2 and gastric cancer risk. 22615049 2012
CUI: C0850666
Disease: Infection caused by Helicobacter pylori
Infection caused by Helicobacter pylori 		0.010 GeneticVariation disease BEFREE Our results suggest that HRH2 -1018 GG homozygote is a risk factor for the severity of gastric mucosal atrophy under the influence of H. pylori infection, especially in older subjects. 22720301 2012
CUI: C0699893
Disease: Skin carcinoma
Skin carcinoma 		0.010 GeneticVariation disease BEFREE Targeting the UV-induced immunosuppression pathway, and using a large population based study of NMSC, we have investigated the risk associated with functional variants in 10 genes (IL10, IL4, IL4R, TNF, TNFR2, HTR2A, HRH2, IL12B, PTGS2, and HAL). 21760883 2011
CUI: C0020452
Disease: Hyperemia
Hyperemia 		0.010 Biomarker disease LHGDN H1 and H2 receptors mediate postexercise hyperemia in sedentary and endurance exercise-trained men and women. 16888049 2006
CUI: C0025202
Disease: melanoma
melanoma 		0.010 AlteredExpression disease LHGDN Histamine elevates the expression of Ets-1, a protooncogen in human melanoma cell lines through H2 receptor. 15848191 2005
CUI: C0014869
Disease: Peptic Esophagitis
Peptic Esophagitis 		0.010 Biomarker disease BEFREE Pharmacological agents, such as histamine H(2) receptor antagonists and acid pump inhibitors, are now the most frequently used treatment for such acid-related diseases as gastroduodenal ulcers and reflux esophagitis. 12667890 2003
CUI: C0030920
Disease: Peptic Ulcer
Peptic Ulcer 		0.010 Biomarker disease BEFREE Pharmacological agents, such as histamine H(2) receptor antagonists and acid pump inhibitors, are now the most frequently used treatment for such acid-related diseases as gastroduodenal ulcers and reflux esophagitis. 12667890 2003
CUI: C0374997
Disease: Helicobacter pylori (H. pylori) infection in conditions classified elsewhere and of unspecified site
Helicobacter pylori (H. pylori) infection in conditions classified elsewhere and of unspecified site 		0.010 Biomarker disease BEFREE Lafutidine, a novel histamine H2-receptor antagonist, vs lansoprazole in combination with amoxicillin and clarithromycin for eradication of Helicobacter pylori. 12662378 2003
CUI: C0677659
Disease: Gastro-esophageal reflux disease with esophagitis
Gastro-esophageal reflux disease with esophagitis 		0.010 Biomarker disease BEFREE Pharmacological agents, such as histamine H(2) receptor antagonists and acid pump inhibitors, are now the most frequently used treatment for such acid-related diseases as gastroduodenal ulcers and reflux esophagitis. 12667890 2003